Cell therapy and humoral alloimmunity post-transplantation: a review of immunoregulatory mechanisms, preclinical studies, and clinical outcomes of cell therapy for transplantation
Year: 2026
Type: article
Abstract: Cellular therapies are a novel therapeutic approach that may safely and effectively suppress acute rejection, minimize the amount of maintenance immunosuppressive drugs needed, and preserve protective immunity against infections. However, less is known about the efficacy of cell therapies for suppression of humoral alloimmunity after transplantation. We review the pre-clinical and clinical solid organ transplant experience with cell therapies that have progressed to clinical trials including CD4 + T regulatory cells (Treg), mesenchymal stem cells (MSC), hematopoietic stem cells (HSC), and regulatory dendritic cells (DCreg) as well as experimental cell therapies in development with antibody-suppressor CXCR5 + CD8 + T cells (CD8 + T Ab-supp cells). While cell therapies have been well tolerated and demonstrate efficacy for immunosuppression minimization or withdrawal, they have not prevented the development of de novo donor specific antibody ( dn DSA) which is known to be associated with reduced long-term allograft survival. The yield of ex vivo expansion protocols, in vivo persistence of cells infused (survival, proliferation, and trafficking), compatibility with conventional immunosuppressive agents, and adverse effects are also examined. This review uniquely analyzes the outcome of cell therapies in transplantation from the perspective of efficacy not only for study endpoints but for suppression of humoral alloimmunity, the compatibility with common maintenance immunosuppressive agents, and opportunities to optimize future cell therapy trial design and data collection.
Source: Frontiers in Immunology
Language: English
Topic: T-cell and B-cell Immunology
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7234613176
